Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Smith, Matthew R.; Sweeney, Christopher J.; Corn, Paul G.; Rathkopf, Dana E.; Smith, David C.; Hussain, Maha; George, Daniel J.; Higano, Celestia S.; Harzstark, Andrea L.; Sartor, A. Oliver; Vogelzang, Nicholas J.; Gordon, Michael; Bono, Johann S. de; Haas, Naomi B.; Logothetis, Christopher J.; Elfiky, Aymen; Scheffold, Christian; Laird, A. Douglas; Schimmöller, Frauke; Basch, Ethan; Scher, Howard I.

doi:10.1200/jco.2013.54.5954

Cited by 120 publications

(100 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…XL184 has been effective against several solid cancers including medullary thyroid cancer, breast, NSCLC, melanoma, and liver cancer Hellerstedt et al 2012;Schoffski et al 2012;Winer et al 2012). The most significant results were observed in the reduction of bone metastatic lesions in castration-resistant prostate cancer (Smith et al 2012). These results raise the question of using multi-targeting versus specific inhibitors in the clinic.…”

Section: Targeting Met-hgf/sf In Cancermentioning

confidence: 56%

MET: A Critical Player in Tumorigenesis and Therapeutic Target

Graveel

Tolbert

Woude

2013

Cold Spring Harbor Perspectives in Biology

106

View full text Add to dashboard Cite

Since its discovery more than 25 years ago, numerous studies have established that the MET receptor is unique among tyrosine kinases. Signaling through MET is necessary for normal development and for the progression of a wide range of human cancers. MET activation has been shown to drive numerous signaling pathways; however, it is not clear how MET signaling mediates diverse cellular responses such as motility, invasion, growth, and angiogenesis. Great strides have been made in understanding the pleotropic aspects of MET signaling using three-dimensional molecular structures, cell culture systems, human tumors, and animal models. These combined approaches have driven the development of MET-targeted therapeutics that have shown promising results in the clinic. Here we examine the unique features of MET and hepatocyte growth factor/scatter factor (HGF/SF) structure and signaling, mutational activation, genetic mouse models of MET and HGF/SF, and MET-targeted therapeutics.

show abstract

Section: Targeting Met-hgf/sf In Cancermentioning

confidence: 56%

MET: A Critical Player in Tumorigenesis and Therapeutic Target

Graveel

Tolbert

Woude

2013

Cold Spring Harbor Perspectives in Biology

106

View full text Add to dashboard Cite

show abstract

“…Results have been disappointing for nintedanib (Molife et al 2014). However, dovitinib (Wan, et al 2014, Porta et al 2015, cabozantinib (Smith et al 2014), pazopanib (Sridhar et al 2014), and axitinib (Eswaraka et al 2014) have shown some promising activity in patient subsets in PCa clinical trials or preclinical models. The structures of the FDA-approved RTK inhibitors sorafenib and sunitinib are shown for comparison.…”

Section: Mouse Models Of Pca and Relevant Aspects Of Angiogenesis/vegmentioning

confidence: 99%

Regulation of vascular endothelial growth factor in prostate cancer

Brot¹,

Ntekim²,

Cardenas³

et al. 2015

Endocrine-Related Cancer

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most common malignancy affecting men in the western world. Although radical prostatectomy and radiation therapy can successfully treat PCa in the majority of patients, up to w30% will experience local recurrence or metastatic disease. Prostate carcinogenesis and progression is typically an androgen-dependent process. For this reason, therapies for recurrent PCa target androgen biosynthesis and androgen receptor function. Such androgen deprivation therapies (ADT) are effective initially, but the duration of response is typically %24 months. Although ADT and taxane-based chemotherapy have delivered survival benefits, metastatic PCa remains incurable. Therefore, it is essential to establish the cellular and molecular mechanisms that enable localized PCas to invade and disseminate. It has long been accepted that metastases require angiogenesis. In the present review, we examine the essential role for angiogenesis in PCa metastases, and we focus in particular on the current understanding of the regulation of vascular endothelial growth factor (VEGF) in localized and metastatic PCa. We highlight recent advances in understanding the role of VEGF in regulating the interaction of cancer cells with tumor-associated immune cells during the metastatic process of PCa. We summarize the established mechanisms of transcriptional and post-transcriptional regulation of VEGF in PCa cells and outline the molecular insights obtained from preclinical animal models of PCa. Finally, we summarize the current state of anti-angiogenesis therapies for PCa and consider how existing therapies impact VEGF signaling.

show abstract

“…10 The CD44v6 peptides also can block VEGF-induced VEGFR-2 activation and signaling. 9 Together, these data add to the relevance of CD44v6 signaling in tumor growth and metastasis. Therefore, we aimed to investigate the impact of CD44v6 in pancreatic cancer metastasis.…”

Section: Introductionmentioning

confidence: 99%

“…20 In both systems MET activation is CD44v6-dependent ( Figure 4A) (as reviewed by Tremmel et al 9 ). We orthotopically injected these cells into immune-compromised mice.…”

Section: Inhibited By a Human Cd44v6 Peptidementioning

confidence: 99%

Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling

et al. 2016

View full text Add to dashboard Cite

Matzke-Ogi, A. et al. (2016) Inhibition of tumor growth and metastasis in pancreatic cancer models by interference with CD44v6 signaling. Gastroenterology, 150(2), 513-525.e10. (doi:10.1053/j.gastro.2015.10.020) This is the author's final accepted version.There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.http://eprints.gla.ac.uk/116680/

show abstract

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Cited by 120 publications

References 10 publications

MET: A Critical Player in Tumorigenesis and Therapeutic Target

MET: A Critical Player in Tumorigenesis and Therapeutic Target

Regulation of vascular endothelial growth factor in prostate cancer

Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling

Contact Info

Product

Resources

About